Published in Blood Weekly, December 13th, 2001
PPTA President Jan M. Bult explained that this program was designed to "demonstrate the leadership of this industry through the development of voluntary initiatives that enhance the continued safety and quality of life-saving plasma therapies worldwide."
The QSEAL program currently has four standards that further reduce the possibility that at-risk donations could enter the manufacturing pool for plasma protein therapies, including: the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.